Ajinomoto to up production of Humanigen's COVID-19 drug

By The Science Advisory Board staff writers

January 27, 2021 -- Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19 drug.

Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody (mAb).

Ajinomoto will simplify the supply chain efforts for Humanigen by providing drug product aseptic fill-finish services at its San Diego facility to support continued clinical trial efforts. Humanigen is actively enrolling patients in a phase III study in the U.S. and Brazil and preparing to submit a potential application for emergency use authorization for lenzilumab.


Copyright © 2021 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?